Document is current
Any future updates will be listed below
-
Authors
Sasada, Shinsuke https://orcid.org/0000-0003-1623-869X
Ohno, Haruya
Taonouchi, Hisae
Teshima, Marino
Takaya, Momoko
Fujimoto, Mutsumi
Ikejiri, Haruka
Amioka, Ai
Shigematsu, Hideo
Okada, Morihito
-
Funding
Funding for this research was provided by:
Hiroshima University
- License Information
-
More Information
Article History
Received: 13 June 2025
Accepted: 25 July 2025
First Online: 6 August 2025
Declarations
:
: Grants or contracts from any entity—SS: Chugai, Daiichi-Sankyo, Eli Lilly, Gilead Sciences, and Nipro. Payment or honoraria for lectures—SS: Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa Kirin. HS: AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa Kirin, MSD, Pfizer, and Taiho. MO: Chugai, and Johnson & Johnson. Stock or stock options—SS: Daiichi-Sankyo.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions.
: Informed consent was obtained from the patient in the case report.
